NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria

Journal of Immunology

Volumn 178, Issue 9, 2007, Pages 5779-5788

  Hansen, Diana S ^a   Bernard, Nicholas J ^a   Nie, Catherine Q ^a   Scholeld, Louis ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MALARIA; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HISTOPATHOLOGY; LYMPHOCYTE MIGRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARASITEMIA; PATHOGENESIS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 34247582292     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.9.5779     Document Type: Article

References (69)

1. Gardiner, C. M. 1999. Natural killer cells. Curr. Biol. 9: R716.
2. O'Connor, G. M., O. M. Hart, and C. M. Gardiner. 2006. Putting the natural killer cell in its place. Immunology 117: 1-10.
3. Marcenaro, E., B. Ferranti, and A. Moretta. 2005. NK-DC interaction: on the usefulness of auto-aggression. Autoimmun. Rev. 4: 520-525.
4. Vitale, M., M. Della Chiesa, S. Carlomagno, D. Pende, M. Arico, L. Moretta, and A. Moretta. 2005. NK-dependent DC maturation is mediated by TNF-α and IFN-γ released upon engagement of the NKp30 triggering receptor. Blood 106: 566-571.
5. Andoniou, C. E., S. L. van Dommelen, V. Voigt, D. M. Andrews, G. Brizard, C. Asselin-Paturel, T. Delate, K. J. Stacey, G. Trinchieri, and M. A. Degli-Esposti. 2005. Interaction-between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol. 6: 1011-1019.
6. Martin-Fontecha, A., L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-γ for Th1 priming. Nat. Immunol. 5: 1260-1265.
7. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2: 957-964.
8. Yokoyama, W. M., and B. F. Plougastel. 2003. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3: 304-316.
9. Brennan, J., D. Mager, W. Jefferies, and F. Takei. 1994. Expression of different members of the Ly-49 gene family defines distinct natural killer cell subsets and cell adhesion properties. J. Exp. Med. 180: 2287-2295.
10. Brennan, J., F. Takei, S. Wong, and D. L. Mager. 1995. Carbohydrate recognition by a natural killer cell receptor, Ly-49C. J. Biol. Chem. 270: 9691-9694.
11. Kärre, K. 2002. NK cells, MHC class I molecules and the missing self. Scand. J. Immunol. 55: 221-228.
12. Dokun, A. O., D. Kim, H. R. Smith, H. S. Kang, D. T. Chu, and W. M. Yokoyama. 2001. Specific and nonspecific NK cell activation during virus infection. Nat. Immunol. 2: 951-956.
13. d target cells leads to Dap-12 phosphorylation and IFN-γ secretion. J. Immunol. 164: 603-611.
14. Brown, M. G., A. A. Scalzo, L. R. Stone, P. Y. Clark, Y. Du, B. Palanca, and W. M. Yokoyama. 2001. Natural killer gene complex (Nkc) allelic variability in inbred mice: evidence for Nkc haplotypes. Immunogenetics 53: 584-591.
15. Mehta, I. K., J. Wang, J. Roland, D. H. Margulies, and W. M. Yokoyama. 2001. Ly49A allelic variation and MHC class I specificity. Immunogenetics 53: 572-583.
16. Delano, M. L., and D. G. Brownstein. 1995. Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J. Virol. 69: 5875-5877.
17. Brownstein, D. G., and L. Gras. 1997. Differential pathogenesis of lethal mouse-pox in congenic DBA/2 mice implicates natural killer cell receptor NKR-P1 in necrotizing hepatitis and the fifth component of complement in recruitment of circulating leukocytes to spleen. Am. J. Pathol. 150: 1407-1420.
18. Scalzo, A. A., P. A. Lyons, N. A. Fitzgerald, C. A. Forbes, W. M. Yokoyama, and G. R. Shellam. 1995. Genetic mapping of Cmv1 in the region of mouse chromosome 6 encoding the NK gene complex-associated loci Ly49 and musNKR-P1. Genomics 27: 435-441.
19. Hansen, D. S., K. J. Evans, M. C. D'Ombrain, N. J. Bernard, A. C. Sexton, L. Buckingham, A. A. Scalzo, and L. Schofield. 2005. The natural killer complex regulates severe malarial pathogenesis and influences acquired immune responses to Plasmodium berghei ANKA. Infect. Immun. 73: 2288-2297.
20. Hansen, D. S., M. A. Siomos, L. Buckingham, A. A. Scalzo, and L. Schofield. 2003. Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. Immunity 18: 391-402.
21. WHO. 1992. World malaria situation 1990. Division of Control of Tropical Diseases. World Health Organization, Geneva. World Health Stat. Q. 45: 257-266.
22. White, N. J., and M. Ho. 1992. The pathophysiology of malaria. Adv. Parasitol. 31: 83-173.
23. Miller, L. H., D. I. Baruch, K. Marsh, and O. K. Doumbo. 2002. The pathogenic basis of malaria. Nature 415: 673-679.
24. Brian de Souza, J., and E. M. Riley. 2002. Cerebral malaria; the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect. 4: 291-300.
25. Schofield, L., and G. E. Grau. 2005. Immunological processes in malaria pathogenesis. Nat. Rev. Immunol. 5: 722-735.
26. Engwerda, C. R., T. L. Mynott, S. Sawhney, J. B. De Souza, Q. D. Bickle, and P. M. Kaye. 2002. Locally up-regulated lymphotoxin α, not systemic tumor necrosis factor α, is the principle mediator of murine cerebral malaria. J. Exp. Med. 195: 1371-1377.
27. Lucas, R., P. Juillard, E. Decoster, M. Redard, D. Burger, Y. Donati, C. Giroud, C. Monso-Hinard, T. De Kesel, W. A. Buurman, et al. 1997. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane- bound TNF in experimental cerebral malaria. Eur. J. Immunol. 27: 1719-1725.
28. Grau, G. E., L. F. Fajardo, P. F. Piguet, B. Allet, P. H. Lambert, and P. Vassalli. 1987. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237: 1210-1212.
29. Amani, V., A. Margarida Vigario, E. Belnoue, M. Marussig, L. Fonseca, D. Mazier, and L. Renia. 2000. Involvement of IFN γ receptor-mediated signaling in pathology and anti-malarial immunity induced by Plasmodium berghei infection. Eur. J. Immunol. 30: 1646-1655.
30. Grau, G. E., H. Heremans, P. F. Piguet, P. Pointaire, P. H. Lambert, A. Billiau, and P. Vassalli. 1989. Monoclonal antibody against interferon γ can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc. Natl. Acad. Sci. USA 86: 5572-5574.
31. + T lymphocytes play a major role in the pathogenesis of murine cerebral malaria. J. Immunol. 137: 2348-2354.
32. Yanez, D. M., D. D. Manning, A. J. Cooley, W. P. Weidanz, and H. C. van der Heyde. 1996. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. J. Immunol. 157: 1620-1624.
33. + T lymphocytes mediate experimental cerebral malaria pathogenesis. J. Immunol. 170: 2221-2228.
34. + T cells in experimental cerebral malaria. J. Immunol. 169: 6369-6375.
35. Hearn, J., N. Rayment, D. N. Landon, D. R. Katz, and J. B. de Souza. 2000. Immunopathology of cerebral malaria: morphological evidence of parasite sequestration in murine brain microvasculature. Infect. Immun. 68: 5364-5376.
36. Franke-Fayard, B., C. J. Janse, M. Cunha-Rodrigues, J. Ramesar, P. Buscher, I. Que, C. Lowik, P. J. Voshol, M. A. den Boer, S. G. van Duinen, et al. 2005. Murine malaria parasite sequestration; CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc. Natl. Acad. Sci. USA 102: 11468-11473.
37. + T cell proliferation. J. Neuroimmunol. 163: 73-83.
38. de Kossodo, S., and G. E. Grau. 1993. Profiles of cytokine production in relation with susceptibility to cerebral malaria. J. Immunol. 151: 4811-4820.
39. Charley, M. R., A. Mikhael, J. Hackett, V. Kumar, and M. Bennett. 1988. Mechanism of anti-asialo GM1 prevention of graft-vs-host disease: identification of allo-antigen activated T cells. J. Invest. Dermatol. 91: 202-206.
40. Wiltrout, R. H., A. Santoni, E. S. Peterson, D. C. Knott, W. R. Overton, R. B. Herberman, and H. T. Holden. 1985. Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages. J. Leukocyte Biol. 37: 597-614.
41. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, and C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754.
42. Bonecchi, R., G. Bianchi, P. P. Bordignon, D. D'Ambrosio, R. Lang, A. Borsatti, S. Sozzani, P. Allavena, P. A. Gray, A. Mantovani, and F. Sinigaglia. 1998. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187: 129-134.
43. Sexton, A. C., R. T. Good, D. S. Hansen, M. C. D'Ombrain, L. Buckingham, K. Simpson, and L. Schofield. 2004. Transcriptional profiling reveals suppressed erythropoiesis, up-regulated glycolysis, and interferon-associated responses in murine malaria. J. Infect. Dis. 189: 1245-1256.
44. Roland, J., V. Soulard, C. Sellier, A. M. Drapier, J. P. Di Santo, P. A. Cazenave, and S. Pied. 2006. NK cell responses to Plasmodium infection and control of intrahepatic parasite development. J. Immunol. 177: 1229-1239.
45. Mohan, K., P. Moulin, and M. M. Stevenson. 1997. Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection. J. Immunol. 159: 4990-4998.
46. Hirunpetcharat, C., F. Finkelman, I. A. Clark, and M. F. Good. 1999. Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease. Parasite Immunol. 21: 319-329.
47. + T cells upon NKR-P1 cross-linking. J. Exp. Med. 183: 2391-2396.
48. Stitz, L., J. Baenziger, H. Pircher, H. Hengartner, and R. M. Zinkernagel. 1986. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities. J. Immunol. 136: 4674-4680.
49. Taylor, T. E., W. J. Fu, R. A. Carr, R. O. Whitten, J. S. Mueller, N. G. Fosiko, S. Lewallen, N. G. Liomba, and M. E. Molyneux. 2004. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat. Med. 10: 143-145.
50. Artavanis-Tsakonas, K., K. Eleme, K. L. McQueen, N. W. Cheng, P. Parham, D. M. Davis, and E. M. Riley. 2003. Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J. Immunol. 171: 5396-5405.
51. Artavanis-Tsakonas, K., and E. M. Riley. 2002. Innate immune response to malaria: rapid induction of IFN-γ from human NK cells by live Plasmodium falciparum-infected erythrocytes. J. Immunol. 169: 2956-2963.
52. Baratin, M., S. Roetynck, C. Lepolard, C. Falk, S. Sawadogo, S. Uematsu, S. Akira, B. Ryffel, J. G. Tiraby, L. Alexopoulou, et al. 2005. Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 102: 14747-14752.
53. Monso-Hinard, C., J. N. Lou, C. Behr, P. Juillard, and G. E. Grau. 1997. Expression of major histocompatibility complex antigens on mouse brain microvascular endothelial cells in relation to susceptibility to cerebral malaria. Immunology 92: 53-59.
54. Fahlen, L., U. Lendahl, and C. L. Sentman. 2001. MHC class I-Ly49 interactions shape the Ly49 repertoire on murine NK cells. J. Immunol. 166: 6585-6592.
55. Held, W., J. D. Coudert, and J. Zimmer. 2003. The NK cell receptor repertoire: formation, adaptation and exploitation. Curr. Opin. Immunol. 15: 233-237.
56. Sørensen, T. L., M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, V. A. Folcik, S. Qin, J. Rottman, F. Sellebjerg, R. M. Strieter, et al. 1999. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103: 807-815.
57. Sørensen, T. L., C. Trebst, P. Kivisakk, K. L. Klaege, A. Majmudar, R. Ravid, H. Lassmann, D. B. Olsen, R. M. Strieter, R. M. Ransohoff, and F. Sellebjerg. 2002. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 127: 59-68.
58. Feferman, T., P. K. Maiti, S. Berrih-Aknin, J. Bismuth, J. Bidault, S. Fuchs, and M. C. Souroujon. 2005. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immunol. 174: 5324-5331.
59. Hancock, W. W., B. Lu, W. Gao, V. Csizmadia, K. Faia, J. A. King, S. T. Smiley, M. Ling, N. P. Gerard, and C. Gerard. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192: 1515-1520.
60. Salomon, I., N. Netzer, G. Wildbaum, S. Schif-Zuck, G. Maor, and N. Karin. 2002. Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 169: 2685-2693.
61. + T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 166: 7617-7624.
62. + T cells in the lungs of patients with HIV infection and T-cell alveolitis. Am. J. Respir. Crit. Care Med. 162: 1466-1473.
63. Shiozawa, F., T. Kasama, N. Yajima, T. Odai, T. Isozaki, M. Matsunawa, Y. Yoda, M. Negishi, H. Ide, and M. Adachi. 2004. Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/lpr mice. Arthritis Res. Ther. 6: R78-R86.
64. Christensen, J. E., A. Nansen, T. Moos, B. Lu, C. Gerard, J. P. Christensen, and A. R. Thomsen. 2004. Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J. Neurosci. 24: 4849-4858.
65. Klein, R. S. 2004. Regulation of neuroinflammation: the role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis. J. Cell. Biochem. 92: 213-222.
66. Luster, A. D., R. Alon, and U. H. von Andrian. 2005. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6: 1182-1190.
67. Ghosh, S., E. Goldin, F. H. Gordon, H. A. Malchow, J. Rask-Madsen, P. Rutgeerts, P. Vyhnalek, Z. Zadorova, T. Palmer, and S. Donoghue. 2003. Natalizumab for active Crohn's disease. N Engl. J. Med. 348: 24-32.
68. Miller, D. H., O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. P. Rice, M. A. Libonati, A. J. Willmer-Hulme, C. M. Dalton, K. A. Miszkiel, and P. W. O'Connor. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348: 15-23.
69. Ulbrich, H., E. E. Eriksson, and L. Lindbom. 2003. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 24: 640-647.